Jeffrey C. Lombardo PharmD, BCOP

Jeffrey Lombardo

Jeffrey C. Lombardo
PharmD, BCOP

Associate Director of the Empire State Patient Safety Assurance Network and research assistant professor for UB

Department of Pharmacy Practice

School of Pharmacy

Contact Information
B2-139 Center of Excellence
701 Ellicott St
Buffalo, NY 14214-8033
Phone: (716) 881-8290
Fax: na

Professional Summary:

Dr. Jeffrey Lombardo is Associate Director for UB’s patient safety organization Empire State Patient Safety Assurance Network. In this role he facilitates organization participation, logistics and implementation with participating sites as well as reviewing data and presenting reports on findings. Working with Medical Oncologists he is tracking patient outcomes and advising physicians on best practices for cancer patients making full use of his specialty pharmacy certification in oncology. Dr. Lombardo is also a member of the SUNY Global Health Institute where he will be bringing his patient safety and oncology expertise to partner schools like the University of the West Indies for various collaborations.In Jamaica he will be partnering with UWI on studies on medical marijuana and pursuing new initiatives for the University at Buffalo’s medication management research network. (MMRN) Additionally Dr. Lombardo is a member of UB‘s Center for Integrated Global Biomedical Sciences.

Dr. Lombardo received his Doctorate in Pharmacy from the University at Buffalo where he currently holds a Research Assistant Professor Title. He has completed research and co-authored several articles on topics involving chemotherapy in the field of solid tumors. Dr. Lombardo has worked in various cancer pharmacies throughout Western New York as well a national oncology specialty pharmacy. These roles provided Dr. Lombardo with expertise in contracting with managed care plans and companies in the pharmaceutical industry. In addition to these accomplishments Dr. Lombardo has exhibited and presented his work at the American Society of Clinical Oncology, American Society of Health System Pharmacists and Value Based Cancer Care Symposiums.”

Education and Training:

  • PharmD, University at Buffalo, SUNY (2003)
  • BS, St John’s University (1993)


  • Associate Director, Pharmaceutical Sciences, University at Buffalo (2016-present)
  • Vice President, OncoMed Pharmacy (2010–2013)
  • Clinical Pharmacist, Roswell Park Cancer Institute (1999–2012)

Research Expertise:

  • Pharmaceutical Oncology: BCOP

Research Centers:

  • Center of Excellence in Bioinformatics and Life Sciences

UB 2020 Strategic Strengths:

  • Health and Wellness Across the Lifespan

Journal Articles:


Evaluative Studies and Case Reports:

Professional Memberships:

  • Consultant; CCS Oncology, Buffalo, NY (2013–present)
  • American College of Clinical Pharmacy
  • Hematology Oncology Pharmacist Association
  • Academy of Managed Care Pharmacy


  • "Medical Marijuana and its role in Clinical Healthcare and Research" UWI Research Days 2016, URD 2016 Signature Event (2016)
  • "Utilizing Health Information Technology to Perform Patient Safety Medication Reviews in a Patient Centered Medical Home Model for Oncology – A Pilot Study" American Society of Health System Pharmacists Midyear Meeting, ASHP, Reiss SN, Lombardo JC, Sayidine F, Felton CM, Morse GD (2012)
  • "Application of Novel Handwriting Recognition Technology for Analyzing Prescription Orders in an Oncology Specialty Pharmacy - A Pilot Study" 24th Annual Meeting & Expo Academy of Managed Care Pharmacy (AMCP), University at Buffalo, Pharmacy (2012)
  • "High Dose Octreotide Acetate for Management of Gastrointestinal Neuroendocrine Tumors" GI ASCO Symposium (2008)
  • "Increase in Splenic Volume Suggesting Unrecognized Portal Hypertension Resulting from Adjuvant FOLFOX Chemotherapy in Colorectal Cancer" ASCO Annual Meeting (2008)
  • "Same day Administration of Pegfilgrastim with Folfox plus or minus Bevacizumab in Colorectal Cancer Patients – A Single Institutional Safety Study" GI ASCO Symposium, Abstract 505 (2008)
  • "Bevacizumab (BV) induced hypertension (HT): a manageable toxicity" ASCO Annual Meeting (2007)
  • "Bevacizumab (BV) related adverse events among various age groups of elderly patients with advanced colorectal cancer" ASCO Annual Meeting, Abstract # 14546 (2007)

School News:

In the Media:

Clinical Specialties:

Clinical Offices:

Insurance Accepted:

Contact Information

B2-139 Center of Excellence
701 Ellicott St
Buffalo, NY 14214-8033
Phone: (716) 881-8290
Fax: na